HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Allergy & Immunology
Sys. Review
P-GemOxD with lopinavir/ritonavir ART yields complete metabolic response in HIV-associated ENKTCL
Treatment plan shows success for rare lymphoma in HIV patient
This case report and literature review describes a middle-aged HIV-1 positive man with stage IE extranodal NK/T-cell lymphoma, nasal type, t…
A specific chemotherapy combination and radiation plan successfully treated a rare type of lymphoma in a man living with HIV.
Frontiers
Oct 8, 2026
Infectious Disease
RCT
Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients
Trial shows favipiravir and lopinavir-ritonavir do not stop COVID-19
This Phase 2a randomized, double-blind, 2x2 factorial placebo-controlled trial evaluated favipiravir and lopinavir-ritonavir in patients wit…
A new trial reveals that combining favipiravir with lopinavir-ritonavir did not show antiviral activity against the virus in patients with C…
Jul 4, 2026
Pulmonology & Critical Care
Cohort
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes
What helps hospitalized COVID-19 patients survive? A new model offers clues
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments.
When COVID-19 hits hard, doctors need better tools to predict who might get worse.
medRxiv
Apr 16, 2026